Pages: 400
Publisher: Chapman & Hall/CRC
Year of Publication: 2016
Author(s) : Harry Yang
Book Description:
Summary
The premise of Quality by Design (QbD) is that the quality of the pharmaceutical product should be based upon a thorough understanding of both the product and the manufacturing process. This state-of-the-art book provides a single source of information on emerging statistical approaches to QbD and risk-based pharmaceutical development. A comprehensive resource, it combines in-depth explanations of advanced statistical methods with real-life case studies that illustrate practical applications of these methods in QbD implementation.
Features
• Presents the first book to provide a single source of information on statistical advances in the implementation of QbD and risk-based methodologies in pharmaceutical development
• Appeals to multitude groups from R&D to manufacturing to quality control and regulatory affairs
• Provides real-life examples, along with sufficient technical detail against a statistical backdrop, to make materials easy to grasp for users with limited statistical knowledge
• Balances a summary of scientific background with regulatory requirements and current/emerging statistical methods
https://www.crcpress.com/Emerging-Non-Clinical-Biostatistics-in-Biopharmaceutical-Development-and/Yang/p/book/9781498704151
